Invitrogen and Cytovance(R) Biologics Collaborate to Develop New Bioreactor Manufacturing...

Invitrogen and Cytovance(R) Biologics Collaborate to Develop New Bioreactor Manufacturing Process of Invitrogen's New CD OptiCHO(TM) Media Platform

OKLAHOMA CITY--(Business Wire)--
Cytovance(R) Biologics LLC, a biopharmaceutical contract
manufacturing company specializing in mammalian cell culture, today
announced the completion of a collaboration with Invitrogen's
PD-Direct(R) Bioprocess Services. Cytovance Biologics has successfully
completed the process transfer and scale-up to 100 L of a fed-batch
bioreactor production process using Invitrogen's new CD OptiCHO(TM)
Medium and CHO CD EfficientFeed(TM) supplement designed specifically
for the fed-batch production process.

"We are very pleased with the results of the scale-up at
Cytovance, which demonstrates the robustness of the integrated
GIBCO(R) media product platforms across processing scales and the
flawless transfer to the Cytovance team," Steve Gorfien, Director,
BioProduction Products and PD-Direct(R) Services.

"The completion of this development collaboration models the
scientific competence we apply to all of our projects," said John
Lightholder, Vice President of Process Science of Cytovance Biologics.

The project with Invitrogen was executed in Cytovance's
multi-product cGMP production facility in Oklahoma City. The 44,000
sq. ft. facility meets the latest international regulatory standards
and is custom-designed for efficient and cost-effective production.
Cytovance specializes in the execution of clinical and commercial
production of antibody and recombinant protein products derived from
cell culture at scales up to 500L (w/v) from both fed-batch and
perfusion processes. This project involved a 2-step scale-up from a
shake flask process through two 5 L bioreactor runs and then into
production in the Cytovance cGMP 100Liter production facility using a
recombinant CHO cell line producing approximately 1 gram per liter.

About Cytovance Biologics

Cytovance Biologics is a biopharmaceutical contract manufacturing
company specializing in the production of therapeutic proteins and
antibodies from mammalian cell culture. In addition to its cGMP
manufacturing services, the company offers process development, cGMP
cell banking and support services from its Oklahoma City, Okla.
facilities. The company's approach couples considerable client-side
experience with the necessary technical and operational expertise to
deliver precision science, agile manufacture, and reasonable business
to that meet international regulatory standards and facilitate
efficient completion of clinical development. For more information on
Cytovance, visit www.cytovance.com.

About Invitrogen's PD-Direct(R) Bioprocess Services

PD-Direct(R) Bioprocess Services (www.invitrogen.com/pddirect) is
a business unit within Invitrogen which specializes in developing cell
lines, cell culture media strategies and process optimization
leveraging Invitrogen products and capabilities for customers to
shorten their development timelines and improve process performance.
GIBCO(R) Bioproduction (www.invitrogen.com/bioproduction) is committed
to the cell culture success of customers with products spanning their
workflow from cell line development through to large scale bioreactor
manufacturing.

Please visit Cytovance Biologics and Invitrogen PD-Direct(R)
Bioprocess Services during the upcoming Bioprocess International
Conference from September 23rd through the 26th at the Disneyland(R)
Hotel Anaheim, CA.

Cytovance(R) Biologics LLC
Molly S. McGlaughlin, 774-553-5418
VP Sales and Business Development
mmcglaughlin@cytovance.com
or
Invitrogen's PD-Direct(R) Bioprocess Services
Trent Carrier
General Manager, PD-Direct(R) Bioprocess Services
pd.direct@invitrogen.com

Copyright Business Wire 2008